Inhibition of HIV-1 Replication by Mutant Tat Peptides

  • Paul M. Loewenstein
  • Masaho Ishino
  • Na’eem Abdullah
  • Maurice Green
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)


The HIV-1 Tat protein is a potent transactivator that is essential for virus replication. We reported previously that chemically synthesized Tat minimal domain peptides and full length Tat (Tat86), in which alanine is substituted for Lys-41, are taken up by cells and antagonize the expression of microinjected HIV-LTR driven CAT gene. We find that several Tat mutant peptides inhibit HIV-1 (HTLV-IIIB) replication. Tat86,41Ala, the most active peptide, inhibits virus replication 95–99% in acutely infected cells when added to the culture medium at concentrations of 10−6 M to 10−7 M; chronically infected cells are also inhibited but to a lesser extent. Tat86,41Ala protects HIV-1 infected cells from virus-induced cytopathogenicity and inhibits syncytia formation. The mechanism of inhibition by Tat mutant peptides is unknown. Unexpectedly, co-transfection of a Tat86 expressing plasmid with plasmids expressing Tat86,41Ala does not inhibit transactivation of endogenous HIV-LTRCAT in HeLa cells. Thus the Tat86,41Ala peptide, when added to cells together with Tat86 can block HIV-LTRCAT transactivation, but not when expressed endogenously from a plasmid. These results imply a novel mechanism of Tat antagonism.


Human Immunodeficiency Virus Transactivation Activity Molt4 Cell Syncytium Formation Fusion Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Berkhout, B., Silverman, R.H., and Jeang, K.-T., 1989, Tat trans-activates the human immunodeficiency virus through a nascent RNA target, Cell 59: 273.PubMedCrossRefGoogle Scholar
  2. Cullen, B.R., and Green, W.C., 1989, Regulatory pathways governing HIV-1 replication, Cell 58: 423.PubMedCrossRefGoogle Scholar
  3. Dingwall, C., Ernberg, I., Gait, M.J., Green, S.M., Heaphy, S., Karn, J., Lowe, A.D., Singh, M., Skinner, M.A., and Valerio, R., 1989, Proc. Natl. Acad. Sci. U.S.A. 86: 6925.PubMedCrossRefGoogle Scholar
  4. Felber, B.K., and Pavlakis, G.N., 1988, A quantitative bioassay for HIV-1 based on trans-activation, Science 239: 184.PubMedCrossRefGoogle Scholar
  5. Frankel, A.D.., and Pabo, C.O., 1988, Cellular uptake of the Tat protein from human immunodeficiency virus, Cell 55: 1189.PubMedCrossRefGoogle Scholar
  6. Frankel, A.D., Biancalana, S., and Hudson, D., 1989, Activity of synthetic peptides from the Tat protein of human immunodeficiency virus, Proc. Natl. Acad. Sci. U.S.A. 86: 7397.PubMedCrossRefGoogle Scholar
  7. Gormon, C.M., Moffatt, L,.F., and Howard, B.H., 1982, Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells, Mol. Cell. Biol. 2: 1044.Google Scholar
  8. Green, M., and Loewenstein, P.M., 1988, Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein, Cell 55: 1179.PubMedCrossRefGoogle Scholar
  9. Green, M., Ishino, M., and Loewenstein, P.M., 1989, Mutational analysis of HIV-1 Tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIVLTR-driven gene expression, Cell 58: 215.PubMedCrossRefGoogle Scholar
  10. Hauber, J., and Cullen, B.R.,1988, Mutational analysis of the transactivation-responsive region of the human immunodeficiency virus type 1 long terminal repeat, J. Virol. 62: 673.Google Scholar
  11. Herskowitz,I., 1987, Functional inactivation of genes by dominant negataive mutations, Nature 329: 219.PubMedCrossRefGoogle Scholar
  12. Kamine, J., Loewenstein, P., and Green, M., 1990, Mapping of HIV-1 Tat protein sequences required for binding to Tar RNA, submitted.Google Scholar
  13. Kent, S.B.H., 1988, Chemical synthesis of peptidesi and proteins, in: “Ann Rev. of Biochem,” C. C. Richardson, ed., Ann. Reviews, Palo Alto.Google Scholar
  14. Mitchell, P.J., and Tjian, R., 1989, Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins, Science 245: 371.PubMedCrossRefGoogle Scholar
  15. Ptashne, M., 1988, How eukaryotic transcriptional activators work, Nature 335: 683.PubMedCrossRefGoogle Scholar
  16. Sharp, P.A., and Marciniak, R.A., 1990, HIV TAR: An RNA enhancer? Cell 59: 229.CrossRefGoogle Scholar
  17. Sodroski, J., Goh, W.C., Rosen, C., Campbell, K., and Haseltine, W.A., 1986, Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity, Nature (London) 322: 470.Google Scholar
  18. Sternson,L.A., 1987, Obstacles to polypeptide delivery, Ann. NY Acad. Sci. 57: 19.CrossRefGoogle Scholar
  19. Tiley, L.S., Brown, P.H., and Cullen, B.R., 1990, Does the human immunodeficiency virus Tat trans-activator contain a discrete activation domain? Virology, in press.Google Scholar
  20. Tochikura, T.S., Nakashima, H., Tanabe,A., and Yamamoto, N., 1988, Human immunodeficiency virus (HIV)-induced cell fusion: Quantification and its application for the simple and rapid screening of anti-HIV substances in vitro, Virology 164: 542.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Paul M. Loewenstein
    • 1
  • Masaho Ishino
    • 1
  • Na’eem Abdullah
    • 1
  • Maurice Green
    • 1
  1. 1.Institute for Molecular VirologySt. Louis University School of MedicineSt. LouisUSA

Personalised recommendations